Clinical Trial Update: The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding temozolomide to conditioning for autologous transplantation in relapsed/refractory CNS lymphoma; study terminated with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma Originating in the Cns

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: B-Cell Lymphoma Originating in the CNS | Phase 2 | Status: TERMINATED | Results posted: 2018-11-20